CoChat

PD‐L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation

Open access

Published version of a preprint

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

PD-L1 expression in melanoma correlates with response to PD-1 pathway-blocking antibodies. Aberrant tumor-cell PD-L1 expression may be oncogene driven and/or induced by IFNγ. Melanomas express PD-L1 in association with tumor-infiltrating lymphocytes (TIL), but the potential contribution of the BRAF V600E mutation (BRAFmut) to induced PD-L1 expression has not been determined. Fifty-two archival melanocytic lesions were assessed for PD-L1 expression, TIL infiltration, and BRAFmut simultaneously. IFNγ-induced PD-L1 expression in cultured melanomas was assessed in parallel according to BRAF status. Melanocyte PD-L1 expression was observed in 40% of specimens, and BRAFmut was observed in 42% of specimens, but no significant concordance was found between these variables. Almost all melanocytes displaying PD-L1 expression were observed to be adjacent to TILs, irrespective of BRAF status. TIL(-) lesions were not more likely to be associated with BRAFmut, when compared with TIL(+) lesions. Baseline expression of PD-L1 by melanoma cell lines was virtually nil, regardless of BRAFmut status, and the intensity of IFN-induced PD-L1 expression in melanoma cell lines likewise did not correlate with BRAF mutational status. PD-L1 expression in melanocytic lesions does not correlate with the BRAFmut. Thus, distinct populations of melanoma patients will likely benefit from BRAF inhibitors versus PD-1 pathway blockade.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-14-0145

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 46

Metadata

Authors
Rodić, N., Anders, R. A., Eshleman, J. R., Lin, M.-T., Xu, H., Kim, J. H., Beierl, K., Chen, S., Luber, B. S., Wang, H., Topalian, S. L., Pardoll, D. M., & Taube, J. M.
Affiliations
Johns Hopkins University (US)
Corresponding author
Taube, Janis M.
Venue
Cancer Immunology Research
Published
2015-02-01
Volume
3
Issue
2
Pages
110-115
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2098598928
Cited by
46
References
27
Citations by year
2023: 1 · 2021: 5 · 2020: 3 · 2019: 9 · 2018: 6 · 2017: 12 · 2016: 4 · 2015: 6
FWCI
3.54
Type
journal article
Language
en
Open access
Locations
  • Cancer Immunology Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (NIH R01 CA142779, R01CA142779, P30CA021765)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords
PD-L1 expression, BRAF V600E mutation, melanocytic lesions, melanoma, tumor-infiltrating lymphocytes, interferon-gamma, PD-1 pathway blockade, BRAF inhibitors, tumor immune microenvironment
MeSH terms
Humans, Interferon-gamma, Melanocytes, Melanoma, Mutation, Neoplasm Proteins, Nevus, Tumor Cells, Cultured, Lymphocytes, Tumor-Infiltrating, Proto-Oncogene Proteins B-raf, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PD‐L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation. https://app.cochat.ai/papers/10.1158/2326-6066.cir-14-0145
The paper
Rodić, N., Anders, R. A., Eshleman, J. R., Lin, M.-T., Xu, H., Kim, J. H., Beierl, K., Chen, S., Luber, B. S., Wang, H., Topalian, S. L., Pardoll, D. M., & Taube, J. M. (2015). PD‐L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-14-0145

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.